US Trial of Gene Therapy AMT-130 Enrolling High-dose Patient Group

US Trial of Gene Therapy AMT-130 Enrolling High-dose Patient Group

313028

US Trial of Gene Therapy AMT-130 Enrolling High-dose Patient Group

A Phase 1/2 clinical trial testing uniQure’s potential gene therapy AMT-130 in people with Huntington’s disease can continue enrollment, according to a positive review by the study’s independent data safety monitoring board (DSMB). The DSMB reviewed safety data from four patients given the higher dose of the therapy, which is delivered directly into the brain. Data from these patients will be shared before the end of the year, according to uniQure’s press release. Enrollment for the final…

You must be logged in to read/download the full post.